search
Back to results

Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya

Primary Purpose

Malaria

Status
Completed
Phase
Phase 1
Locations
Kenya
Study Type
Interventional
Intervention
PfSPZ Vaccine
Normal Saline
Sponsored by
Sanaria Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Malaria focused on measuring Plasmodium falciparum, PfSPZ Vaccine

Eligibility Criteria

5 Months - 9 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy children 5 months - 9 years inclusive (Part 1) and healthy infants 5-12 months inclusive (Part 2)
  • HIV negative
  • Able to participate for the duration of the study.
  • Parents/guardians over the age of 18 years able and willing to provide informed consent/permission. The consent/permission will be in writing. For adult parents or guardians who are illiterate, an impartial witness can sign the consent/permission form on behalf of the parent and the parent/guardian will provide a thumb print.

Exclusion Criteria:

  • Positive HIV test or breastfeeding infants or children of a known HIV positive mother (per Kenyan guidelines, these HIV exposed breastfeeding children should be on cotrimoxazole)
  • Refusal of HIV testing
  • Elevated ALT (liver function test) ≥2x ULN ( ALT >84 U/L)
  • Abnormal hematological parameters defined as: hemoglobin < 8 g/dl, WBC <1500 / mm3, neutrophils <750/ mm3, platelet count <75.000/ mm3
  • Abnormal renal function test with creatinine >0.9 mg/dL
  • Known sickle cell disease and other inherited blood cell disorders like thalassemia and G6PD deficiency
  • Current use of systemic immunosuppressant pharmacotherapy
  • Current significant medical condition (cardiac, hepatic, renal, or hematological) or evidence of any other serious underlying medical condition identified by medical history, physical examination, or laboratory examination
  • History of a splenectomy
  • History of neurologic disorder (including seizures, other than uncomplicated febrile seizures)
  • Known allergy to any component of the vaccine formulation, history of anaphylactic response to mosquito-bites, or known allergy to first or second line anti-malarials used to treat malaria
  • Plan to participate in another investigational vaccine/drug research during or within 1 month of this study end
  • Prior participation in a malaria vaccine trial
  • Participation in the PfSPZ Vaccine Trial Part 1 (for Part 2 only)
  • History of any other illness or condition which, in the investigator's judgment, may substantially increase the risk associated with the subject's participation in the protocol or compromise the scientific objectives
  • Child/orphan in institutional care

Sites / Locations

  • Center for Global Health Research, KEMRI

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm 11

Arm 12

Arm 13

Arm 14

Arm 15

Arm 16

Arm 17

Arm 18

Arm 19

Arm 20

Arm 21

Arm 22

Arm 23

Arm 24

Arm 25

Arm 26

Arm 27

Arm 28

Arm 29

Arm 30

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

Part 1: Grp 1A - PfSPZ Vaccine

Part 1: Grp 1A - Normal Saline

Part 1: Grp 1B - PfSPZ Vaccine

Part 1: Grp 1B - Normal Saline

Part 1: Grp 1C - PfSPZ Vaccine

Part 1: Grp 1C - Normal Saline

Part 1: Grp 2A - PfSPZ Vaccine

Part 1: Grp 2A - Normal Saline

Part 1: Grp 2B - PfSPZ Vaccine

Part 1: Grp 2B - Normal Saline

Part 1: Grp 2C - PfSPZ Vaccine

Part 1: Grp 2C - Normal Saline

Part 1: Grp 2D - PfSPZ Vaccine

Part 1: Grp 2D - Normal Saline

Part 1: Grp 2E - PfSPZ Vaccine

Part 1: Grp 2E - Normal Saline

Part 1: Grp 3A - PfSPZ Vaccine

Part 1: Grp 3A - Normal Saline

Part 1: Grp 3B - PfSPZ Vaccine

Part 1: Grp 3B - Normal Saline

Part 1: Grp 3C - PfSPZ Vaccine

Part 1: Grp 3C - Normal Saline

Part 1: Grp 3D - PfSPZ Vaccine

Part 1: Grp 3D - Normal Saline

Part 1: Grp 3E - PfSPZ Vaccine

Part 1: Grp 3E - Normal Saline

Part 2: Group 1 - PfSPZ Vaccine

Part 2: Group 2 - PfSPZ Vaccine

Part 2: Group 3 - PfSPZ Vaccine

Part 2: Group 4 - Normal Saline

Arm Description

Children aged 5-9 years (inclusive) of age will be enrolled in this group. N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination.

Children aged 5-9 years (inclusive) of age will be enrolled in this group. N=4; Normal saline administered DVI, as a single vaccination.

Children aged 5-9 years (inclusive) of age will be enrolled in this group. N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 1A dose has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.

Children aged 5-9 years (inclusive) of age will be enrolled in this group. N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 1A dose has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.

Children aged 5-9 years (inclusive) of age will be enrolled in this group. N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.

Children aged 5-9 years (inclusive) of age will be enrolled in this group. N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.

Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=8; Dose of 1.35 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns.

Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns.

Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=8; Dose of 2.7 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2A has been shown to be well-tolerated and without safety concerns.

Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2A has been shown to be well-tolerated and without safety concerns.

Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns.

Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns.

Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.

Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.

Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.

Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.

Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=8; Dose of 1.35 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns.

Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns.

Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=8; Dose of 2.7 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3A has been shown to be well-tolerated and without safety concerns.

Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3A has been shown to be well-tolerated and without safety concerns.

Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3B has been shown to be well-tolerated and without safety concerns.

Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3B has been shown to be well-tolerated and without safety concerns.

Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.

Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.

Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.

Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.

Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2. N=104; the highest dose that is determined to be safe and well tolerated in the Part 1 trial, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 1.8 x 10^6 PfSPZ per dose.

Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2. N=104; the second highest dose, which is half of the highest dose, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 9.0 x 10^5 PfSPZ per dose.

Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2. N=104; a lower dose (half of the second highest dose) administered in 3 doses by DVI at 0, 8, 16 weeks. Likely dosage will be 4.5x 10^5 PfSPZ per dose.

Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2. N=104; a placebo arm, will receive normal saline by DVI, 3 times at 8 week intervals.

Outcomes

Primary Outcome Measures

Part 1 - Incidence and type of adverse events (AE)
Incidence and type of solicited and unsolicited adverse events including breakthrough malaria infections and clinical laboratory assessments (hematological, liver and renal function) will be collected within 28 days after each vaccination. Proportions of participants with AEs and frequencies of individual AEs will be calculated and compared against participants in the same age category and dose group receiving placebo.
Part 1 - Incidence and type of possibly/probably or definitely related serious adverse events (SAEs)
Incidence of all hospitalizations, deaths, disabilities caused by at least possibly related SAEs during study participation
Part 1 - Assessment of Pf-specific antibodies in the different age categories and to the different vaccine doses
Collection of blood samples for antibodies on day 8 after each vaccination. Following vaccination serum will be taken and an assessment of Plasmodium falciparum (Pf)f-specific antibodies against specific malaria proteins such as the circumsporozoite protein (CSP) PfCSP and whole Pf sporozoites (SPZ) will be determined by enzyme-linked immunosorbent assay (ELISA) and automated immunofluorescence assay (aIFA) respectively.
Part 2 - Incidence and type of adverse events in infants 5-12 months of age following administration of PfSPZ Vaccine
Incidence and type of solicited and unsolicited adverse events including breakthrough malaria infections and clinical laboratory assessments (hematological, liver and renal function) will be collected during 28 days after each vaccination.
Part 2 - Incidence and type of possibly/probably or definitely related serious adverse events (SAEs) following administration of PfSPZ Vaccine
Incidence of all hospitalizations, deaths, disabilities caused by at least possibly related to the study product during the 12-month follow-up period.
Part 2 - Assessment of Pf-specific antibodies in infants of 5-12 months to three vaccinations of PfSPZ Vaccine
Collection of blood samples for antibodies on day 8 after vaccination 1 and 2 and day 15 after the third PfSPZ vaccination. Following vaccination serum will be taken and an assessment of Plasmodium falciparum (Pf)f-specific antibodies against specific malaria proteins such as the circumsporozoite protein (CSP) PfCSP and whole Pf sporozoites (SPZ) will be determined by enzyme-linked immunosorbent assay (ELISA) and automated immunofluorescence assay (aIFA) respectively.
Part 2 - Ratio of Pf positive blood smear (+BS) in experimental arm to Pf +BS in placebo arm to determine efficacy of PfSPZ Vaccine during 6 months after last dose
Efficacy against malaria infection of PfSPZ Vaccine administered to infants 5-12 months of age in 3 doses by passive and active surveillance for naturally acquired Pf infection, measured by blood smear microscopy, during 6 months following the last vaccine dose.

Secondary Outcome Measures

Part 2 - Ratio of Pf +BS in experimental arm to Pf +BS in placebo arm to determine efficacy of PfSPZ Vaccine during 12 months after last dose
Efficacy against malaria of PfSPZ Vaccine administered to infants 5-12 months of age in 3 doses by passive and active surveillance for naturally acquired Pf infection, measured by blood smear microscopy, during 12 months following the last vaccine dose will be performed and the prevalence ratio of the prevalence of malaria infection by blood smear between each dose study arm and placebo will be compared.
Part 2 - Ratio of Pf positive PCR in experimental arm to Pf positive PCR in placebo arm to determine efficacy against submicroscopic malaria infection of PfSPZ Vaccine following 6 and 12 months after the last dose
Efficacy against submicroscopic malaria infection of PfSPZ Vaccine administered to infants 5-12 months of age in 3 doses by passive and active surveillance for naturally acquired Pf infection, measured by PCR, during 6 and 12 months following the last vaccine dose.
Part 2 - Assessment of Pf-specific antibodies, parasite-specific T cell responses and RNA sequencing.
Collection of blood samples for Anti PfSPZ antibodies and RNA sequencing at different time points. Following vaccination serum will be taken and an assessment of Plasmodium falciparum (Pf)f-specific antibodies against specific malaria proteins such as the circumsporozoite protein (CSP) PfCSP and whole Pf sporozoites (SPZ) will be determined by enzyme-linked immunosorbent assay (ELISA) and automated immunofluorescence assay (aIFA). For assessment of parasite-specific T cell responses, PBMCs will be assessed by multi-parameter flow cytometry and / or ELISPOT, and intracellular cytokine staining. RNA sequencing from whole blood will be performed by processing the RNA and performing deep sequencing. Analysis of gene expression will be performed to develop biomarkers and predictors of protection.
Part 2 - Assessment of Pf-specific antibodies, parasite-specific T cell responses and RNA sequencing to determine correlation of immune response with efficacy
Comparison of the immune response at different time points and the protection against naturally acquired Pf infection. Following vaccination serum will be taken and an assessment of Plasmodium falciparum (Pf)f-specific antibodies against specific malaria proteins such as the circumsporozoite protein (CSP) PfCSP and whole Pf sporozoites (SPZ) will be determined by enzyme-linked immunosorbent assay (ELISA) and automated immunofluorescence assay (aIFA). For assessment of parasite-specific T cell responses, PBMCs will be assessed by multi-parameter flow cytometry and / or ELISPOT, and intracellular cytokine staining. RNA sequencing from whole blood will be performed by processing the RNA and performing deep sequencing. Analysis of gene expression will be performed to develop biomarkers and predictors of protection.

Full Information

First Posted
February 9, 2016
Last Updated
April 18, 2019
Sponsor
Sanaria Inc.
Collaborators
Kenya Medical Research Institute, Centers for Disease Control and Prevention, National Institutes of Health (NIH), University of Maryland
search

1. Study Identification

Unique Protocol Identification Number
NCT02687373
Brief Title
Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya
Official Title
Safety, Tolerability and Efficacy of PfSPZ Vaccine Administered by Direct Venous Inoculation (DVI) to Healthy Children and Infants 5 Months Through 9 Years of Age Living in an Area of High Malaria Transmission in Western Kenya: Age De-escalation and Dose Escalation and a Double Blind, Randomized Placebo-Controlled Trial for Safety and Efficacy
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
July 21, 2016 (Actual)
Primary Completion Date
August 2018 (Actual)
Study Completion Date
August 14, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanaria Inc.
Collaborators
Kenya Medical Research Institute, Centers for Disease Control and Prevention, National Institutes of Health (NIH), University of Maryland

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will be conducted in Siaya County in Nyanza Province, western Kenya. Healthy children aged 5 months through 9 years of age living within approximately 10 km of the study clinic(s) (Siaya County Referral Hospital, or Wagai dispensary, a government health facility in Wagai division) will be eligible for participation in Part 1; healthy infants aged 5 months - 12 months inclusive will be eligible for Part 2.
Detailed Description
Part 1: Age De-Escalation and Dose Escalation Part 1 of this trial is a randomized blinded evaluation of the safety and tolerability of PfSPZ Vaccine administered by DVI in healthy children and infants living in an area of high malaria transmission. A maximum of 156 children from 5 months to 9 years inclusive at vaccination will be enrolled and randomized to receive vaccine or normal saline (NS) placebo by DVI. Total participation time in the dose escalation trial ranges from 5-16 weeks per participant from screening visit to close out or 4 - 12 weeks from enrolment to close out. Vaccination will begin in the 5-9 year age group at a dosage of 4.5 x10^5 PfSPZ. A single vaccination will be administered by DVI to each of 12 participants aged 5-9 years (inclusive) of age, 8 receiving PfSPZ vaccine and 4 participants receiving NS placebo by DVI, with treatment allocation randomized and double-blind. Once the initial dose has been shown to be well tolerated and without safety concerns, the next higher dose of 9.0 x 10^5 PfSPZ will be administered to a second group of 5-9 year olds. Once this has been shown to be well tolerated and without safety concerns, the highest dose of 1.8 x 10^6 PfSPZ will be given to a third group of 5-9 year olds and concurrently the lowest dose (1.35 x10^5) will be given to a same-sized group of younger children aged 13-59 months. Two weeks later, this dose will be escalated to 2.7 x10^5 PfSPZ in a second group of children aged 13-59 months. Only once this dose is shown to be well-tolerated and without safety concerns will PfSPZ Vaccine, at the lowest dose, be given to infants aged 5 - 12 months. Within each age group, dosages will increase stepwise until they reach 1.8 x 10^6 PfSPZ, with the initiation of each group staggered by at least 2 weeks, provided that no safety thresholds are surpassed. In each dosage level, the PfSPZ Vaccine or placebo will be provided to a limited number of participants each day (e.g. 3 participants from one age group on days 1 through 4). The PfSPZ Vaccine dose will only be increased to the next dose level when safety has been assessed in subjects of the first group. The same procedures will be followed for all doses. Children in all age groups who are enrolled to receive the 2 highest doses, i.e. 9.0 x 10^5 or 1.8 x 10^6 PfSPZ, or placebo, will receive a second vaccination of the same dose after 8 weeks, provided the first vaccination at this dose level did not show safety signals. Part 2: Safety and Efficacy Part of this study will be conducted in the outpatient areas of Siaya County Referral Hospital, a large referral hospital in western Kenya and in Wagai dispensary. A maximum of 416 infants from 5 M to 12 M inclusive at vaccination will be enrolled into this safety and efficacy trial and randomized to receive PfSPZ Vaccine at a dose determined during Part 1 of the trial (dose escalation), but likely to be 4.5x10^5, 9.0 x10^5and 1.8 x 10^6 administered x 3 doses ; and NS placebo administered x 3 doses, all by DVI administered at 8 week intervals. Participants (N = 416, with 104 in each study arm) will be randomly assigned in a double blinded fashion to receive one of the following PfSPZ Vaccine regimes: Group 1 (N=104): The highest dose that is determined to be safe and well tolerated in the Part 1 trial, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 1.8 x 10^6 PfSPZ per dose. Group 2 (N=104): The second highest dose, which is half of the highest dose, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 9.0 x 10^5 PfSPZ per dose. Group 3 (N=104): A lower dose (half of the second highest dose) administered in 3 doses by DVI at 0, 8, 16 weeks. Likely dosage will be 4.5x 10^5 PfSPZ per dose. Group 4 (N=104): A placebo arm, will receive NS by DVI, 3 times at 8 week intervals.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malaria
Keywords
Plasmodium falciparum, PfSPZ Vaccine

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
337 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Part 1: Grp 1A - PfSPZ Vaccine
Arm Type
Experimental
Arm Description
Children aged 5-9 years (inclusive) of age will be enrolled in this group. N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination.
Arm Title
Part 1: Grp 1A - Normal Saline
Arm Type
Placebo Comparator
Arm Description
Children aged 5-9 years (inclusive) of age will be enrolled in this group. N=4; Normal saline administered DVI, as a single vaccination.
Arm Title
Part 1: Grp 1B - PfSPZ Vaccine
Arm Type
Experimental
Arm Description
Children aged 5-9 years (inclusive) of age will be enrolled in this group. N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 1A dose has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
Arm Title
Part 1: Grp 1B - Normal Saline
Arm Type
Placebo Comparator
Arm Description
Children aged 5-9 years (inclusive) of age will be enrolled in this group. N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 1A dose has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
Arm Title
Part 1: Grp 1C - PfSPZ Vaccine
Arm Type
Experimental
Arm Description
Children aged 5-9 years (inclusive) of age will be enrolled in this group. N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
Arm Title
Part 1: Grp 1C - Normal Saline
Arm Type
Placebo Comparator
Arm Description
Children aged 5-9 years (inclusive) of age will be enrolled in this group. N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
Arm Title
Part 1: Grp 2A - PfSPZ Vaccine
Arm Type
Experimental
Arm Description
Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=8; Dose of 1.35 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns.
Arm Title
Part 1: Grp 2A - Normal Saline
Arm Type
Placebo Comparator
Arm Description
Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns.
Arm Title
Part 1: Grp 2B - PfSPZ Vaccine
Arm Type
Experimental
Arm Description
Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=8; Dose of 2.7 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2A has been shown to be well-tolerated and without safety concerns.
Arm Title
Part 1: Grp 2B - Normal Saline
Arm Type
Placebo Comparator
Arm Description
Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2A has been shown to be well-tolerated and without safety concerns.
Arm Title
Part 1: Grp 2C - PfSPZ Vaccine
Arm Type
Experimental
Arm Description
Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns.
Arm Title
Part 1: Grp 2C - Normal Saline
Arm Type
Placebo Comparator
Arm Description
Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns.
Arm Title
Part 1: Grp 2D - PfSPZ Vaccine
Arm Type
Experimental
Arm Description
Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
Arm Title
Part 1: Grp 2D - Normal Saline
Arm Type
Placebo Comparator
Arm Description
Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
Arm Title
Part 1: Grp 2E - PfSPZ Vaccine
Arm Type
Experimental
Arm Description
Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
Arm Title
Part 1: Grp 2E - Normal Saline
Arm Type
Placebo Comparator
Arm Description
Children aged 13-59 months (inclusive) of age will be enrolled in this group. N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
Arm Title
Part 1: Grp 3A - PfSPZ Vaccine
Arm Type
Experimental
Arm Description
Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=8; Dose of 1.35 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns.
Arm Title
Part 1: Grp 3A - Normal Saline
Arm Type
Placebo Comparator
Arm Description
Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns.
Arm Title
Part 1: Grp 3B - PfSPZ Vaccine
Arm Type
Experimental
Arm Description
Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=8; Dose of 2.7 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3A has been shown to be well-tolerated and without safety concerns.
Arm Title
Part 1: Grp 3B - Normal Saline
Arm Type
Placebo Comparator
Arm Description
Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3A has been shown to be well-tolerated and without safety concerns.
Arm Title
Part 1: Grp 3C - PfSPZ Vaccine
Arm Type
Experimental
Arm Description
Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3B has been shown to be well-tolerated and without safety concerns.
Arm Title
Part 1: Grp 3C - Normal Saline
Arm Type
Placebo Comparator
Arm Description
Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3B has been shown to be well-tolerated and without safety concerns.
Arm Title
Part 1: Grp 3D - PfSPZ Vaccine
Arm Type
Experimental
Arm Description
Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
Arm Title
Part 1: Grp 3D - Normal Saline
Arm Type
Placebo Comparator
Arm Description
Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
Arm Title
Part 1: Grp 3E - PfSPZ Vaccine
Arm Type
Experimental
Arm Description
Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
Arm Title
Part 1: Grp 3E - Normal Saline
Arm Type
Placebo Comparator
Arm Description
Children aged 5-12 months (inclusive) of age will be enrolled in this group. N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
Arm Title
Part 2: Group 1 - PfSPZ Vaccine
Arm Type
Experimental
Arm Description
Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2. N=104; the highest dose that is determined to be safe and well tolerated in the Part 1 trial, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 1.8 x 10^6 PfSPZ per dose.
Arm Title
Part 2: Group 2 - PfSPZ Vaccine
Arm Type
Experimental
Arm Description
Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2. N=104; the second highest dose, which is half of the highest dose, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 9.0 x 10^5 PfSPZ per dose.
Arm Title
Part 2: Group 3 - PfSPZ Vaccine
Arm Type
Experimental
Arm Description
Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2. N=104; a lower dose (half of the second highest dose) administered in 3 doses by DVI at 0, 8, 16 weeks. Likely dosage will be 4.5x 10^5 PfSPZ per dose.
Arm Title
Part 2: Group 4 - Normal Saline
Arm Type
Placebo Comparator
Arm Description
Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2. N=104; a placebo arm, will receive normal saline by DVI, 3 times at 8 week intervals.
Intervention Type
Biological
Intervention Name(s)
PfSPZ Vaccine
Intervention Description
Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Intervention Type
Other
Intervention Name(s)
Normal Saline
Intervention Description
0.9% Sodium chloride
Primary Outcome Measure Information:
Title
Part 1 - Incidence and type of adverse events (AE)
Description
Incidence and type of solicited and unsolicited adverse events including breakthrough malaria infections and clinical laboratory assessments (hematological, liver and renal function) will be collected within 28 days after each vaccination. Proportions of participants with AEs and frequencies of individual AEs will be calculated and compared against participants in the same age category and dose group receiving placebo.
Time Frame
Collected from day of each vaccination until day 28 post vaccination
Title
Part 1 - Incidence and type of possibly/probably or definitely related serious adverse events (SAEs)
Description
Incidence of all hospitalizations, deaths, disabilities caused by at least possibly related SAEs during study participation
Time Frame
Collected from day of first vaccination until close out visit (28 days for 3 lower doses, 84 days for 2 higher doses)
Title
Part 1 - Assessment of Pf-specific antibodies in the different age categories and to the different vaccine doses
Description
Collection of blood samples for antibodies on day 8 after each vaccination. Following vaccination serum will be taken and an assessment of Plasmodium falciparum (Pf)f-specific antibodies against specific malaria proteins such as the circumsporozoite protein (CSP) PfCSP and whole Pf sporozoites (SPZ) will be determined by enzyme-linked immunosorbent assay (ELISA) and automated immunofluorescence assay (aIFA) respectively.
Time Frame
Collected 1 week after each vaccination
Title
Part 2 - Incidence and type of adverse events in infants 5-12 months of age following administration of PfSPZ Vaccine
Description
Incidence and type of solicited and unsolicited adverse events including breakthrough malaria infections and clinical laboratory assessments (hematological, liver and renal function) will be collected during 28 days after each vaccination.
Time Frame
Collected from day of each vaccination until day 28 post vaccination
Title
Part 2 - Incidence and type of possibly/probably or definitely related serious adverse events (SAEs) following administration of PfSPZ Vaccine
Description
Incidence of all hospitalizations, deaths, disabilities caused by at least possibly related to the study product during the 12-month follow-up period.
Time Frame
Collected from day of first vaccination through the 12-month follow-up period.
Title
Part 2 - Assessment of Pf-specific antibodies in infants of 5-12 months to three vaccinations of PfSPZ Vaccine
Description
Collection of blood samples for antibodies on day 8 after vaccination 1 and 2 and day 15 after the third PfSPZ vaccination. Following vaccination serum will be taken and an assessment of Plasmodium falciparum (Pf)f-specific antibodies against specific malaria proteins such as the circumsporozoite protein (CSP) PfCSP and whole Pf sporozoites (SPZ) will be determined by enzyme-linked immunosorbent assay (ELISA) and automated immunofluorescence assay (aIFA) respectively.
Time Frame
Collected 1 week after the first and second vaccination and 2 weeks after the third vaccination.
Title
Part 2 - Ratio of Pf positive blood smear (+BS) in experimental arm to Pf +BS in placebo arm to determine efficacy of PfSPZ Vaccine during 6 months after last dose
Description
Efficacy against malaria infection of PfSPZ Vaccine administered to infants 5-12 months of age in 3 doses by passive and active surveillance for naturally acquired Pf infection, measured by blood smear microscopy, during 6 months following the last vaccine dose.
Time Frame
2 weeks to 6 months after the last vaccine dose
Secondary Outcome Measure Information:
Title
Part 2 - Ratio of Pf +BS in experimental arm to Pf +BS in placebo arm to determine efficacy of PfSPZ Vaccine during 12 months after last dose
Description
Efficacy against malaria of PfSPZ Vaccine administered to infants 5-12 months of age in 3 doses by passive and active surveillance for naturally acquired Pf infection, measured by blood smear microscopy, during 12 months following the last vaccine dose will be performed and the prevalence ratio of the prevalence of malaria infection by blood smear between each dose study arm and placebo will be compared.
Time Frame
2 weeks to 12 months after the last vaccine dose
Title
Part 2 - Ratio of Pf positive PCR in experimental arm to Pf positive PCR in placebo arm to determine efficacy against submicroscopic malaria infection of PfSPZ Vaccine following 6 and 12 months after the last dose
Description
Efficacy against submicroscopic malaria infection of PfSPZ Vaccine administered to infants 5-12 months of age in 3 doses by passive and active surveillance for naturally acquired Pf infection, measured by PCR, during 6 and 12 months following the last vaccine dose.
Time Frame
2 weeks to 6 and 12 months after the last vaccine dose
Title
Part 2 - Assessment of Pf-specific antibodies, parasite-specific T cell responses and RNA sequencing.
Description
Collection of blood samples for Anti PfSPZ antibodies and RNA sequencing at different time points. Following vaccination serum will be taken and an assessment of Plasmodium falciparum (Pf)f-specific antibodies against specific malaria proteins such as the circumsporozoite protein (CSP) PfCSP and whole Pf sporozoites (SPZ) will be determined by enzyme-linked immunosorbent assay (ELISA) and automated immunofluorescence assay (aIFA). For assessment of parasite-specific T cell responses, PBMCs will be assessed by multi-parameter flow cytometry and / or ELISPOT, and intracellular cytokine staining. RNA sequencing from whole blood will be performed by processing the RNA and performing deep sequencing. Analysis of gene expression will be performed to develop biomarkers and predictors of protection.
Time Frame
Before the first vaccination, 1 week after vaccination 1 and 2, 2 weeks after vaccination 3 and at 6 months and 12 months after the last vaccination
Title
Part 2 - Assessment of Pf-specific antibodies, parasite-specific T cell responses and RNA sequencing to determine correlation of immune response with efficacy
Description
Comparison of the immune response at different time points and the protection against naturally acquired Pf infection. Following vaccination serum will be taken and an assessment of Plasmodium falciparum (Pf)f-specific antibodies against specific malaria proteins such as the circumsporozoite protein (CSP) PfCSP and whole Pf sporozoites (SPZ) will be determined by enzyme-linked immunosorbent assay (ELISA) and automated immunofluorescence assay (aIFA). For assessment of parasite-specific T cell responses, PBMCs will be assessed by multi-parameter flow cytometry and / or ELISPOT, and intracellular cytokine staining. RNA sequencing from whole blood will be performed by processing the RNA and performing deep sequencing. Analysis of gene expression will be performed to develop biomarkers and predictors of protection.
Time Frame
Entire study period
Other Pre-specified Outcome Measures:
Title
Ratio of Pf +BS in experimental arm to Pf +BS in placebo arm to determine efficacy against Pf infection at certain parasite thresholds in each study arm
Description
Passive and active surveillance for naturally acquired Pf infection, measured by blood smear microscopy, during 12 months following the last dose in each study arm will be performed and the Pf infection by blood smear at parasite density >400 or >5000 parasites per microliter between each dose study arm and placebo will be compared.
Time Frame
2 weeks to 12 months after last vaccination
Title
Ratio of Pf +BS in experimental arm to Pf +BS in placebo arm to determine efficacy against clinical malaria and malaria hospitalization in each study arm
Description
Passive and active surveillance for naturally acquired Pf infection of > 5000 parasites per microliter measured by blood smear microscopy associated with fever (clinical malaria) and/or hospitalization as well as hospitalization for severe malarial anemia, during 12 months following the last dose in each study arm will be performed and each study arm will be compared with the placebo group.
Time Frame
2 weeks to 12 months after last vaccination
Title
Effect of vaccination on anemia
Description
Measure hemoglobin at 6 months and 12 months after the last vaccination and compare hemoglobin levels in each study arm with the placebo group.
Time Frame
6 months and 12 months after last vaccination

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Months
Maximum Age & Unit of Time
9 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy children 5 months - 9 years inclusive (Part 1) and healthy infants 5-12 months inclusive (Part 2) HIV negative Able to participate for the duration of the study. Parents/guardians over the age of 18 years able and willing to provide informed consent/permission. The consent/permission will be in writing. For adult parents or guardians who are illiterate, an impartial witness can sign the consent/permission form on behalf of the parent and the parent/guardian will provide a thumb print. Exclusion Criteria: Positive HIV test or breastfeeding infants or children of a known HIV positive mother (per Kenyan guidelines, these HIV exposed breastfeeding children should be on cotrimoxazole) Refusal of HIV testing Elevated ALT (liver function test) ≥2x ULN ( ALT >84 U/L) Abnormal hematological parameters defined as: hemoglobin < 8 g/dl, WBC <1500 / mm3, neutrophils <750/ mm3, platelet count <75.000/ mm3 Abnormal renal function test with creatinine >0.9 mg/dL Known sickle cell disease and other inherited blood cell disorders like thalassemia and G6PD deficiency Current use of systemic immunosuppressant pharmacotherapy Current significant medical condition (cardiac, hepatic, renal, or hematological) or evidence of any other serious underlying medical condition identified by medical history, physical examination, or laboratory examination History of a splenectomy History of neurologic disorder (including seizures, other than uncomplicated febrile seizures) Known allergy to any component of the vaccine formulation, history of anaphylactic response to mosquito-bites, or known allergy to first or second line anti-malarials used to treat malaria Plan to participate in another investigational vaccine/drug research during or within 1 month of this study end Prior participation in a malaria vaccine trial Participation in the PfSPZ Vaccine Trial Part 1 (for Part 2 only) History of any other illness or condition which, in the investigator's judgment, may substantially increase the risk associated with the subject's participation in the protocol or compromise the scientific objectives Child/orphan in institutional care
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martina Oneko, MD
Organizational Affiliation
Kenya Medical Research Institute, Centre for Global Health Research, Kisumu, Kenya
Official's Role
Principal Investigator
Facility Information:
Facility Name
Center for Global Health Research, KEMRI
City
Kisian
State/Province
Siaya County
Country
Kenya

12. IPD Sharing Statement

Citations:
PubMed Identifier
34518679
Citation
Oneko M, Steinhardt LC, Yego R, Wiegand RE, Swanson PA, Kc N, Akach D, Sang T, Gutman JR, Nzuu EL, Dungani A, Kim Lee Sim B, Oloo PN, Otieno K, Bii DK, Billingsley PF, James ER, Kariuki S, Samuels AM, Jongo S, Chebore W, Abdulla S, Daubenberger C, Mpina M, Styers D, Potter GE, Abarbanell G, Richie TL, Hoffman SL, Seder RA. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nat Med. 2021 Sep;27(9):1636-1645. doi: 10.1038/s41591-021-01470-y. Epub 2021 Sep 13.
Results Reference
derived
PubMed Identifier
32444192
Citation
Oneko M, Cherop YR, Sang T, Gutman JR, Wiegand R, Nyang'au EM, Odila AD, Akach D, Hamel MJ, Samuels AM, Kariuki S, Abebe Y, Nzuu EL, Wijayalath W, James ER, Sim BKL, Billingsley PF, Richie TL, Hoffman SL, Seder RA, Steinhardt LC. Feasibility of direct venous inoculation of the radiation-attenuated Plasmodium falciparum whole sporozoite vaccine in children and infants in Siaya, western Kenya. Vaccine. 2020 Jun 15;38(29):4592-4600. doi: 10.1016/j.vaccine.2020.05.008. Epub 2020 May 19.
Results Reference
derived
PubMed Identifier
31555824
Citation
Steinhardt LC, Richie TL, Yego R, Akach D, Hamel MJ, Gutman JR, Wiegand RE, Nzuu EL, Dungani A, Kc N, Murshedkar T, Church LWP, Sim BKL, Billingsley PF, James ER, Abebe Y, Kariuki S, Samuels AM, Otieno K, Sang T, Kachur SP, Styers D, Schlessman K, Abarbanell G, Hoffman SL, Seder RA, Oneko M. Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoite Vaccine Administered by Direct Venous Inoculation to Infants and Young Children: Findings From an Age De-escalation, Dose-Escalation, Double-blind, Randomized Controlled Study in Western Kenya. Clin Infect Dis. 2020 Aug 14;71(4):1063-1071. doi: 10.1093/cid/ciz925.
Results Reference
derived

Learn more about this trial

Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya

We'll reach out to this number within 24 hrs